期刊
CLINICAL AND EXPERIMENTAL MEDICINE
卷 16, 期 3, 页码 307-316出版社
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10238-015-0355-4
关键词
Multiple myeloma (MM); Bone marrow stromal cells (BMSCs); Drug resistance; microRNA-202 (miR-202); B cell-activating factor (BAFF)
资金
- National Natural Science Foundation of China [81301498, 81271920]
- Jiangsu Provincial Program for Medical Innovation Teams and Leading Talents [LJ201133]
- Scientific Research Subject of Jiangsu Province Health Department [H201422]
- six major human resources project of Jiangsu Province [20012-WS-119]
- Translational Medicine Project of Affiliated Hospital of Nantong University [TDF-zh201407]
Bone marrow stromal cells (BMSCs) up-regulate B cell-activating factor (BAFF) in multiple myeloma. Increasing experimental evidence has shown that microRNAs play a causal role in hematology tumorigenesis. In this study, we characterized the role of miR-202 in regulating the expression of BAFF in BMSCs. It was found that expressions of BAFF mRNA and protein were increased in BMSCs treated with miR-202 inhibitor. The growth rate of miR-202 mimics transfection cells was significantly lower than that of non-transfected cells. The expression of Bcl-2 protein was down-regulated, and Bax protein was up-regulated after miR-202 mimics transfection. Over-expression of miR-202 in BMSCs rendered MM cells more sensitive to bortezomib. More significantly, the regulatory effect of miR-202 could inhibit the activation of NF-kappa B pathway in BMSCs. These results suggest that miR-202 functions as a modulator that can negatively regulate BAFF by inhibiting MM cell survival, growth, and adhesion in the bone marrow microenvironment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据